Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

STUDY SPOTLIGHT: Recruitment of Patients for a Phase III SLE Clinical Trial

A Pharm-Olam Video

About the Video

During the planning of a Phase III Systemic Lupus Erythematosus (SLE) anti-B cell therapy, the Sponsor company called on Pharm-Olam to assist in the identification and enrollment of patients.

The purpose of the study was to determine the viability of a biological agent in treating SLE patients whose disease state was severe, aggressively advancing and poorly controlled. SLE is a notoriously difficult-to-diagnose autoimmune disorder with no known cure.

To read the full case study, click here.



 

How can we help you create a healthier world?

Talk to one of our experts today.

Please choose one.

Contact Us